Loading...
•
Dec 31, 2019
Editas Q4 2019 Earnings Report
Editas Medicine's Q4 2019 results were announced with a net loss, increased R&D expenses, and a strengthened executive leadership team.
Key Takeaways
Editas Medicine reported a net loss of $37.8 million for the fourth quarter of 2019, compared to a net loss of $25.1 million for the same period in 2018. The company's cash, cash equivalents, and marketable securities totaled $457.1 million as of December 31, 2019. They are advancing their pipeline of in vivo CRISPR and engineered cell medicines.
First patient dosing with EDIT-101 (AGN-151587) expected in 1Q20.
Plan to file IND for EDIT-301 for sickle cell disease by end of 2020.
Research collaboration with Sandhill Therapeutics accelerates IND-enabling studies for allogeneic healthy donor NK program to treat solid tumors in mid-2020.
Company's cash, cash equivalents and marketable securities of $457.1 million at December 31, 2019.
Editas
Editas
Editas Revenue by Segment
Revenue by Segment
Collab & R&D Rev Revenue
CapyFin.com Forward Guidance
Editas Medicine plans to dose the first patient with EDIT-101 in Q1 2020, file an IND for EDIT-301 by the end of 2020, and initiate IND-enabling studies for an allogeneic NK cell medicine in mid-2020.
Positive Outlook
- Announcement of first patient dosing with EDIT-101 (AGN-151587) expected in 1Q20
- Plan to file IND for EDIT-301 for sickle cell disease by end of 2020
- Research collaboration with Sandhill Therapeutics accelerates IND-enabling studies for allogeneic healthy donor NK program to treat solid tumors in mid-2020
- Advancing broader pipeline of in vivo CRISPR medicines
- Progressing engineered cell medicines for hemoglobinopathies and cancers
Challenges Ahead
- Uncertainties inherent in the initiation and completion of pre-clinical studies and clinical trials
- Availability and timing of results from pre-clinical studies and clinical trials
- Whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials
- Expectations for regulatory approvals to conduct trials or to market products
- Availability of funding sufficient for foreseeable and unforeseeable operating expenses and capital expenditure requirements